Avivagen Announces Publication of Peer-Reviewed Article in Food and Chemical Toxicology Journal

OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV: VIV, OTCQB: VIVXF) (“Avivagen”), a life sciences company focused on the development and commercialization of products for livestock, companion animals and human applications that safely improve food intake and support immune function, supporting overall health and performance, is pleased to announce that its scientific paper titled “Safety and Absorption of Fully Oxidized Beta-Carotene” (the active ingredient in the company’s OxC-beta™ product line) has been published in the Journal of Food and Chemical Toxicology. A link to the article is provided below.

“With any innovative product, uptake and uptake requires a solid understanding of that product’s benefits and safety and requires careful consideration. Avivagen has worked tirelessly to showcase the multiple compelling use cases of OxC- beta and concurrent proven safety. This new peer-reviewed publication, one of ten such publications on OxC-beta, represents the cumulative work on our product’s compelling safety profile. This pioneering work by Dr. Graham Burton, co-founder of Avivagen, and his team are laying important foundations for obtaining new regulatory approvals for OxC-beta in the United States and around the world, for multiple use cases and with strong scientific and expected by our end-market customers,” said Kym Anthony, CEO of Avivagen. “We look forward to sharing these results with existing and new customers and providing them to regulators around the world as we seek to further expand our access to major markets.”

Please refer to the full content of the peer-reviewed publication on “Safety and Absorption of Fully Oxidized Beta-Carotene” by following the link below: https://www.sciencedirect.com/science/article/pii/S0278691522005853?via%3Dihub

About OxC-beta™ Technology

β-carotene has been recognized primarily for the health benefits it provides when converted into vitamin A through a biochemical reaction with oxygen in the body. Avivagen has discovered that the spontaneous oxidation of β-carotene produces a mixture of oxidation compounds other than vitamin A that also provide important health benefits. The β-carotene oxidation compound blend, OxC-beta, a product developed by Avivagen, does not contain β-carotene or vitamin A, indicating that its health benefits come solely from the oxidation compounds themselves. same. Incorporating OxC-beta into products for livestock, pets and humans has a range of practical benefits. A peer-reviewed article has just been published in the prestigious journal Food and Chemical Toxicology (https://doi.org/10.1016/j.fct.2022.113387) reported that OxC-beta has a very high margin of safety and the finding that the natural counterpart of OxC-beta is present at significant levels in mouse tissues and blood. A standard toxicology study conducted in rats established a no-observed-adverse-effect-level that is several thousand times higher than the level of OxC-beta supplementation used in livestock, pets, and humans. These results are very important in establishing the safety of OxC-beta with respect to the product’s regulatory approvals in various major jurisdictions.

About Avivagen

Avivagen is a life sciences company focused on the development and commercialization of products for livestock, companion animals and human applications that, by safely supporting immune function, promote overall health and performance. It is a public company listed on the TSX Venture Exchange under the symbol VIV and headquartered in Ottawa, Canada at the partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The content of the website is expressly not incorporated by reference in this press release.

About OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen’s discoveries of β-carotene and other carotenoids, compounds that give certain fruits and vegetables their vibrant colors. By supporting immune function, the technology provides a non-antibiotic way to promote health and growth. OxC-beta™ Livestock is a proprietary product proven to be an effective and economical alternative to antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, Vietnam, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to eliminate all antibiotics from food as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product works as well and, sometimes, in some respects, better than antibiotics in feed.

Forward-looking statements

This press release contains certain forward-looking statements based on management’s current expectations. Forward-looking statements involve risks and uncertainties associated with Avivagen Inc.’s business and the environment in which the company operates. All statements contained herein that are not statements of historical fact can be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “target”, “hope”, “probable”, “may”, “plan”, “eventually”, “potentially”, “pursue”, “seem”, “should”, “if”, “will”, “would” and similar expressions.

The statements set forth in this press release regarding the potential positive impacts expected from the publication of the article referenced above, the possibility of further regulatory approvals and expanded use cases for Avivagen’s products, future growth and Avivagen’s prospects and the potential for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For example, Avivagen’s products may not be accepted by the market or approved by regulatory authorities in new jurisdictions or for new applications and may not be widely accepted as substitutes for antibiotics as growth promoters in livestock feed due to many factors, many of which are beyond Avivagen’s control. . Readers are referred to the risk factors associated with the activities of Avivagen presented in the most recent management report and analysis of the financial situation of Avivagen available at www.SEDAR.com. Except as required by law, Avivagen undertakes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

Jacob L. Thornton